{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T12:47:38Z","timestamp":1784119658672,"version":"3.55.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ijcard.2025.133683","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T15:05:29Z","timestamp":1753974329000},"page":"133683","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Effects of oral semaglutide on cardiovascular outcomes: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"440","author":[{"given":"Thiago Gorayeb","family":"Rebelo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria L\u00facia Brito","family":"de Araujo Paysano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo Tadeu Freitas Uch\u00f4a","family":"Matheus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danilo Monteiro","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Benevides","family":"Said","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francinny Alves","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2025.133683_bb0005","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0140-6736(24)02317-1","article-title":"Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants","volume":"404","author":"Zhou","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2025.133683_bb0010","series-title":"Type 2 Diabetes","author":"Goyal","year":"2023"},{"key":"10.1016\/j.ijcard.2025.133683_bb0015","series-title":"Hyperglycemia and Cardiovascular Disease in Type 2 Diabetes","author":"Laakso","year":"1999"},{"key":"10.1016\/j.ijcard.2025.133683_bb0020","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2217\/fca-2018-0045","article-title":"Type-2 diabetes mellitus and cardiovascular disease","volume":"14","author":"Henning","year":"2018","journal-title":"Future Cardiol."},{"key":"10.1016\/j.ijcard.2025.133683_bb0025","series-title":"Cardiovascular Disease and Risk Management: Standards of Care in Diabetes\u20142025","year":"2025"},{"key":"10.1016\/j.ijcard.2025.133683_bb0030","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-018-0728-6","article-title":"Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017","author":"Einarson","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.ijcard.2025.133683_bb0035","series-title":"Heart Disease and Diabetes","author":"Kalayi","year":"2023"},{"key":"10.1016\/j.ijcard.2025.133683_bb0040","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1080\/00325481.2015.1090295","article-title":"User\u2019s guide to the mechanism of action and clinical use of GLP-1 receptor agonists","volume":"127","author":"Shaefer","year":"2015","journal-title":"Postgrad. Med."},{"key":"10.1016\/j.ijcard.2025.133683_bb0045","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2025.133683_bb0050","series-title":"Compare and Contrast the Glucagon-like Peptide-1 Receptor Agonists (GLP1RAS)","author":"Latif","year":"2024"},{"key":"10.1016\/j.ijcard.2025.133683_bb0055","series-title":"Glucagon-like Peptide-1 Receptor Agonists","author":"Collins","year":"2024"},{"key":"10.1016\/j.ijcard.2025.133683_bb0060","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1080\/13696998.2020.1722678","article-title":"Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis","volume":"23","author":"Hansen","year":"2020","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.ijcard.2025.133683_bb0065","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2025.133683_bb0070","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2501006","article-title":"Oral Semaglutide and cardiovascular outcomes in high-risk type 2 diabetes","author":"McGuire","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2025.133683_bb0075","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2025.133683_bb0080","article-title":"Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial","author":"Mahaffey","year":"2024","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2025.133683_bb0085","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.2337\/dc19-0898","article-title":"Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PioNEER 8 trial","volume":"42","author":"Zinman","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ijcard.2025.133683_bb0090","doi-asserted-by":"crossref","DOI":"10.1111\/jdi.14265","article-title":"Adherence and treatment discontinuation of oral semaglutide and once-weekly semaglutide injection at 12-month follow-up: Japanese real-world data","author":"Horii","year":"2024","journal-title":"J. Diabet. Investig."},{"key":"10.1016\/j.ijcard.2025.133683_bb0095","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.2337\/dc19-0749","article-title":"PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes","volume":"42","author":"Aroda","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ijcard.2025.133683_bb0100","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S2213-8587(19)30192-5","article-title":"Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial","volume":"7","author":"Mosenzon","year":"2019","journal-title":"Lancet Diabetes Endocrinol."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527325007260?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527325007260?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T09:34:01Z","timestamp":1764668041000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527325007260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":20,"alternative-id":["S0167527325007260"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2025.133683","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of oral semaglutide on cardiovascular outcomes: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2025.133683","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"133683"}}